A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
Completed · Phase 1
Conditions studied: Solid Malignant Tumor
In brief
This first in human phase 1 study of TVB-2640 is being conducted in patients with advanced stage solid malignant tumors. This research is being done to find out how safe and useful TVB-2640 is for patients who have received previous cancer therapy, and for whom no therapy exists that would be curative or might provide significant benefit. TVB-2640 belongs to a class of drugs called fatty acid synthase inhibitors (FASN inhibitors). This means that they interfere with the body's (and the tumor's) ability to use a substance called fatty acid synthase (FASN). Research has shown that some tumors appear to need FASN to keep growing.
Key facts
- Study ID
- NCT02223247
- Run by
- Sagimet Biosciences Inc.
- People needed
- 180
- Starts
- 2013-11-01
- Expected to finish
- 2017-06-01
- Last updated by the study team
- 2017-08-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Scottsdale, Arizona, United States
- Study site — Denver, Colorado, United States
- Study site — Sarasota, Florida, United States
- Study site — Oklahoma City, Oklahoma, United States
- Study site — Nashville, Tennessee, United States
- Study site — Dallas, Texas, United States
- Study site — San Antonio, Texas, United States
- Study site — Charthouse Square, London, United Kingdom
- Study site — London, United Kingdom
- Study site — Manchester, United Kingdom
- Study site — West Smithfield, London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.